Danone and Yakult to accelerate R&D cooperation

By Stephen Daniells

- Last updated on GMT

Related tags Danone Groupe danone

France's Danone and Japan's Yakult will continue their strategic
alliance involving closer cooperation on R&D and entry into new
markets, maintaining their positions as leaders in the probiotics
market.

The strengthening of the alliance will see two more Danone executives sitting on the Yakult board, bringing the Danone presence up to four. But Danone will not be increasing its shareholding in Yakult, the two companies confirmed. Danone is already the largest shareholder in Yakult with a 20 per cent stake. Danone's first 5 per cent stake in Yakult, bought in 2000, did little to improve cooperation in the probiotics sector. When Danone upped its stake in Yakult to 20 per cent in April 2003, buying €300 million in shares on the open market, the Japanese firm faced speculation that its shareholder would attempt a hostile takeover bid. Both companies have now announced that Danone will maintain its stake at 20.02 per cent until 2012. "The steady strengthening of this cooperation backed by a permanent liaison bureau had made for a climate of trust that Groupe Danone and Yakult Honsha now wish to reinforce through even closer ties at the highest level of their organisations,"​ stated Danone. The partnership will include the establishment of joint ventures in Vietnam and India, and the founding of a Global Probiotic Council. "Building on these new bases, the partners will be accelerating the pace of co-operation, particularly in research,"​ stated Danone. "In this spirit, Yakult Honsha has just granted Groupe Danone's Daniel Carasso Research Center a license for its YIF-Scan, a unique, high precision system that quantifies bacteria, targeting gene sequences (RNA and DNA) specific to particular intestinal bacteria."​ Sales in probiotics are growing rapidly, as consumers become increasingly aware of the importance of gut health. In Europe, dairy is the biggest area for human food applications. Probiotics are set to reach $137.9 million (€118.5m) in 2010 in Europe, with the US market projected to reach $394 million, according to Frost & Sullivan.

Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Related suppliers

Follow us

Products

View more

Webinars